Sun, Mar 1, 2015, 2:46 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • docihi docihi Mar 21, 2011 7:29 AM Flag

    Great news

    "Roche has indicated that it anticipates making AT LEAST ONE (my caps) regulatory submission in 2011 to seek approval to commercialize GDC-0449." Why say "at least one"? They could have simply said that they anticipate filing for BCC. Not only is this great news for patients, but it should move the price considerably. I think it will make CNBC and the major network news programs. If so, the near-term (~3-5 days) price move may be substantial. I hope the future medical meeting is soon. I think that the mid-term price move MIGHT be a little muted until the safety study is finalized. We may soon be in the position of having to make an exit point decision. While we know that ongoing trials will show if GDC-0449 works on other tumor types, with all of the other trials going on these results can only help potential investors to wonder if the drug is efficacious for those other tumor types.
    For new investors, as desert says:

    Thanks to desert (now you can sleep better). And to hedgehog for the detailed molecular biology/biochemistry stuff.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.08-0.07(-2.22%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Aruba Networks, Inc.
NASDAQFri, Feb 27, 2015 4:00 PM EST
Vulcan Materials Company
NYSEFri, Feb 27, 2015 4:00 PM EST